Glaucoma

Glaucoma, which is a leading cause of blindness in the US, causes fluid build-up in the eye. Fortunately, it can now be treated with a remarkable laser technology that can halt the disease’s progress. The technology combines an aiming beam, laser scalpel and video camera within a tube 1/18” in diameter. The new procedure, called endoscopic photocoagulation (ECP), targets the fluid-producing structures of a patient’s eye to reduce the pressure that causes glaucoma.

In a majority of cases, ECP eliminates or greatly reduces the need for medicated drops, which are now the most common treatment for the affliction. In addition, medicated drops are not covered by most insurance plans, while ECP is covered. ECP surgery can also provide relief from the side effects of eye drops, which may include redness, allergic reactions, headaches and elevated blood pressure.

ECP can be performed as a stand-alone procedure or in conjunction with cataract surgery. Performed on an outpatient basis, the surgery takes just a few minutes to complete. After a short recovery period, patients are able to resume their normal routine. Patients can stop using their eye drops anywhere from one to six weeks post-op.

Glaucoma affects approximately 3 million Americans. The disease is symptomless, but can be detected by a simple test usually performed during a routine vision exam. Individuals with a family history of glaucoma, African Americans and the elderly are considered at elevated risk of glaucoma. Annual testing is recommended for everyone over 60 years old.

“It truly is remarkable,” says Dr. Kim Robbins of Robbins Eye Center. “Glaucoma is called ‘the sneak thief of sight’ because of its slow and painless progression. Now, with a quick and safe outpatient procedure, we can often stop its terrible effects.”

For more information on ECP, contact Robbins Eye Center at:
(203) 371-5800